Trial
NCT06637527
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
Phase IITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Okyo Pharma Ltd
Collaborators
Tufts Medical Center
Condition
Neuropathic Pain
Intervention
OK-101 0.05%
Why stopped
Study ended early to expedite development and enable earlier FDA discussions. Prior Phase 2 data (240 patients) showed favorable safety and placebo-like tolerability. Closure was not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-15